Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…

Related Keywords

Ottawa ,Ontario ,Canada ,Vietnam ,Republic Of ,Uruguay ,Brunei ,Laos ,China ,Shanghai ,Brazil ,Guangzhou ,Guangdong ,New York ,United States ,Colombia ,Argentina ,Indonesia ,Peru ,Beijing ,Panama ,Australia ,Cambodia ,New Zealand ,San Francisco ,California ,Chile ,India ,United Kingdom ,Malaysia ,Maryland ,Mexico ,Thailand ,Philippines ,Suzhou ,Jiangsu ,South Africa ,Australian ,Chinese ,Canadian ,Carolyn Rogers ,Gabriel Friedman ,Barbara Shecter ,Justin Trudeau ,Joe Oconnor ,Junshi Biosciences ,David Rosenberg ,Junshi Bioscience ,Zhi Li ,Pr Team ,Ir Team ,Shanghai Junshi Biosciences Co Ltd ,Drug Administration ,Harbour Authority ,Australian Government Department Of Health ,Therapeutic Goods Administration ,Postmedia Network Inc ,National Medical Products Administration Of China ,National Post ,Canada Revenue Agency ,Regulatory Agency ,National Drug List For Basic Medical Insurance ,Biosciences Announces ,Year Financial Results ,Provides Corporate ,Joeo Connor ,Victoria Wells ,Financial Times ,Financial Post ,New York Times ,Deuremidevir Hydrobromide Tablets ,National Medical Products Administration ,Biologics License Application ,Australian Government ,Aged Care ,New Chemical Entity ,National Drug List ,Basic Medical Insurance ,Work Related Injury Insurance ,Maternity Insurance ,Postmedia Network ,Top Stories ,Rxilient Biotech ,Shareholders Agreement ,For Global ,Minister Justin ,Trans Mountain ,